---
schema_version: "secwatch.filing_event.v1"
accession: "0001411690-26-000019"
form_type: "8-K"
ticker: "BNGO"
cik: "0001411690"
company_name: "Bionano Genomics, Inc."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:35:12.802586+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bionano Genomics CEO Erik Holmlin terminated; Chairman Al Luderer named interim CEO

## Summary
- CEO Erik Holmlin terminated effective May 5, 2026; will serve as advisor under consulting agreement.
- Board appoints Chairman Albert Luderer as interim CEO and interim principal financial officer.
- Luderer receives $600k base salary, up to $400k bonus, and $4k/month housing/travel stipend.
- Chris Twomey appointed Lead Independent Director to support governance during transition.
- Company will immediately commence search for a permanent CEO.

## SEC filing metadata
- accession: 0001411690-26-000019
- form_type: 8-K
- ticker: BNGO
- cik: 0001411690
- company_name: Bionano Genomics, Inc.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411690/000141169026000019/0001411690-26-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411690/000141169026000019/bngo-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001411690-26-000019
- JSON: https://secwatch.observer/filing/0001411690-26-000019.json
- Plain text: https://secwatch.observer/filing/0001411690-26-000019.txt

## Source-grounded claims
- claim_id: d3360a8193
  claim: Albert A. Luderer was appointed as Interim Chief Executive Officer at Bionano Genomics, Inc..
  evidence_excerpt: As of the Effective Date, the Board appointed Albert A. Luderer, Ph.D., who currently serves as the Company’s Chairman of the Board, as the Company’s Interim Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411690/000141169026000019/0001411690-26-000019-index.htm
- claim_id: edf2ccb15b
  claim: Erik Holmlin was terminated as President and Chief Executive Officer at Bionano Genomics, Inc..
  evidence_excerpt: On May 5, 2026 (the “Effective Date”), Bionano Genomics, Inc. (the “Company”) R. Erik Holmlin, Ph.D. was terminated as the Company’s President and Chief Executive Officer, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411690/000141169026000019/0001411690-26-000019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.